CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
18F-氟脱氧葡萄糖-正电子发射断层扫描/计算机断层扫描在淋巴瘤中的应用
英文原题：18F-Fluorodeoxyglucose-positron emission tomography/computed tomography in Lymphoma.
查看英文原题
18F-Fluorodeoxyglucose-positron emission tomography/computed tomography in Lymphoma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
FDG-PET/CT 是霍奇金和非霍奇金淋巴瘤亚型中基于 Lugano 的分期、Deauville 评分的疗效评估和预后判断的核心。定量指标，尤其是总代谢肿瘤体积，已成为强大的独立预后生物标志物。在霍奇金淋巴瘤中，中期 PET 成功指导治疗降级，而在 DLBCL 中，中期 PET 仍具有预后价值，但不具有治疗可操作性。FDG-PET/CT 是 CAR-T 治疗期间多时间点评估的有价值的预后生物标志物，并指导桥接治疗。在靶向治疗时代，借助 PET 影像组学和深度学习，更复杂的 PET 预后和疗效评估标准正在涌现，这需要标准化。
展开英文摘要原文
FDG-PET/CT is central to Lugano-based staging, Deauville-scored response assessment, and prognostication across Hodgkin and non-Hodgkin lymphoma subtypes. Quantitative metrics, particularly total metabolic tumor volume, have emerged as powerful independent prognostic biomarkers. In Hodgkin's lymphoma, interim PET successfully guides treatment de-escalation, while in DLBCL, interim PET remains prognostic but not therapeutically actionable.
FDG-PET/Ct is a valuable prognostic biomarker for multi-time point assessment during CAR-T therapy, and guides bridging therapy. More sophisticated PET prognostic and response assessment criteria are emerging in the era of targeted therapies with the help of PET radiomics and deep learning, which needs standardization.
论文信息
- 作者
- Bedmutha A、Alkukhun L、Weiler-Sagie M、Takalkar AM
- 第一作者单位
- Department of Radiology & Imaging Sciences, Emory University, Atlanta, GA, USA.United States
- 通讯作者单位
- Department of Radiology & Imaging Sciences, Emory University, Atlanta, GA, USA. Electronic address: amol.madan.takalkar@emory.edu.United States
- 文献类型
- 综述
- 期刊
- PET clinics2026 Aug 13
- 原文标识
- PubMed 42595627 · DOI 10.1016/j.cpet.2026.06.020